Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Asia Green Biotechnology Corp. (C:ASIA)

Business Focus: Alternative Medicine

Sector:  Healthcare Industry:  Pharmaceuticals
 
Company Contact
Address: 707 - 7th Avenue SW, Suite 1150
Calgary AB T2P 3H6
Tel: N/A
Website: asiacannabiscorp.com
IR: See website
Key People
N/A    
Business Overview
Asia Green Biotechnology Corp. is a Canada-based early-stage international agro-technology company. The Company is focused on the development, evaluation, testing, application and, ultimately, supply to the market of organic hybridization technology and certain products derived from that technology (the Technology). The Company is engaged in planting, growth and harvesting of new and valuable strains of hemp and related crops in commercial quantities under the terms of the license agreement with InPlanta Biotechnology Inc. (InPlanta) and the evaluation and development of medicinal and related cannabinoid extracts under the terms of license agreements with Swysh Inc. (Swysh), and Pathway Rx Corp (Pathway Rx). It is in the process of establishing and implementing research and development programs in Cambodia and Thailand and continues to evaluate the potential to expand its business operations to other countries in the region.
Financial Overview
For the nine months ended 30 September 2023, Asia Green Biotechnology Corp revenues was not reported. Net loss decreased 48% to C$68K. Lower net loss reflects Consulting fees decrease from C$94K (expense) to C$0K, Research and development decrease from C$7K (expense) to C$0K.
Reporting Currency: Canadian Dollars
Enterprise value: $0.76M as of Sep 30, 2023
Annual revenue (TTM): $0.00M as of Sep 30, 2023
EBITDA (TTM): -$0.11M as of Sep 30, 2023
Net annual income (TTM): -$0.13M as of Sep 30, 2023
Free cash flow (TTM): -$0.10M as of Sep 30, 2023
Net Debt Last Fiscal Year: $0.25M as of Sep 30, 2023
Shares outstanding: 36,247,100 as of Sep 30, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization